Bradley Merrill Thompson

News
Motor vehicles stalled in a traffic jam
Commentary: Digital health companies should stay away from FDA in 2021
By Bradley Merrill Thompson 05:20 pm December 23, 2020
As the agency's workload swells with the weight of a public health emergency, digital health companies on a timeline should consider whether their products truly warrant a regulatory submission, writes Epstein Becker & Green's Bradley Merrill Thompson.

The Daily Brief Newsletter

Get daily news updates from Healthcare IT News.
Your subscription has been saved.
Something went wrong. Please try again.

More Stories

A pharmacist doing an inventory using a digital tablet.
There is no escaping making investments in cybersecurity...
group of healthcare workers talking over hospital bed
Modernizing clinical placement to accelerate clinician training and recruitment
A male doctor sits with another man and they are looking at SDOH data on a mobile device.
Tufts Medical Center to pilot nutrition screening in EHR
Lynn Carroll, COO of HSBlox
Using tech to get to health equity-social determinants of health link
Yale New Haven Health
Yale New Haven radiologists boost CT scan reviews with AI
Dubai Health Authority
The current state of Dubai’s healthcare digital transformation journey
Leah Dewey, VP of clinical and consumer engagement operations at Cotiviti.
Payers have a part to play in addressing health disparities
Christie Teigland, vice president of research science and advanced analytics at Inovalon.
Medicare Advantage plans' star ratings to be affected by Health Equity Index